Murray Patrick T, Devarajan Prasad, Levey Andrew S, Eckardt Kai U, Bonventre Joseph V, Lombardi Raul, Herget-Rosenthal Stefan, Levin Adeera
Department of Medicine, Section of Nephrology, MC 5100, Room S-511, University of Chicago Hospitals, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
Clin J Am Soc Nephrol. 2008 May;3(3):864-8. doi: 10.2215/CJN.04851107. Epub 2008 Feb 20.
Acute Kidney Injury (AKI) is common worldwide, and associated with significant morbidity, mortality, and resource utilization. The RIFLE system of staging AKI correlates with survival in AKI in several settings. A similar AKI definition and staging system that also incorporates lesser degrees of serum creatinine elevation was proposed at the inaugural Acute Kidney Injury Network (AKIN) meeting in 2005. At the Second AKIN meeting in Vancouver, Canada in September 2006, our group developed a research agenda that would test the utility of these diagnostic and staging criteria to predict patient outcomes in a variety of clinical settings and patient groups.
DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Three-day, international, consensus conference. A multidisciplinary stakeholder committee was divided into work groups. Recommendations for clinical practice and for future research were developed by the committee as an iterative process. This procedure consisted of a literature review phase and focus group interactions with presentations to the entire committee.
We first proposed a conceptual framework of disease that describes a series of AKI stages, antecedents and outcomes, and allows a description of research recommendations based on transition between AKI stages. We further proposed methods for testing of the definition and development of research questions to establish the utility of new biomarkers for the diagnosis and staging of AKI and associated illnesses.
Retrospective studies should be conducted to initiate the process of validating the AKIN definition of AKI, followed by comprehensive prospective studies that incorporate sampling for emerging AKI biomarkers.
急性肾损伤(AKI)在全球范围内都很常见,与显著的发病率、死亡率及资源利用相关。AKI的RIFLE分期系统在多种情况下都与AKI患者的生存率相关。2005年首届急性肾损伤网络(AKIN)会议上提出了一个类似的AKI定义及分期系统,该系统还纳入了血清肌酐升高程度较轻的情况。在2006年9月于加拿大温哥华召开的第二届AKI会议上,我们团队制定了一项研究议程,以测试这些诊断和分期标准在各种临床环境和患者群体中预测患者预后的效用。
设计、背景、参与者及测量方法:为期三天的国际共识会议。一个多学科利益相关者委员会被分成了多个工作组。委员会通过反复的过程制定了临床实践和未来研究的建议。这个过程包括文献综述阶段以及与焦点小组的互动,并向整个委员会进行汇报。
我们首先提出了一个疾病概念框架,该框架描述了一系列AKI阶段、前驱因素及预后,并允许基于AKI阶段之间的转变来描述研究建议。我们还进一步提出了测试定义和提出研究问题的方法,以确定新生物标志物在AKI及相关疾病诊断和分期中的效用。
应开展回顾性研究以启动验证AKIN的AKI定义的过程,随后进行全面的前瞻性研究,其中包括采集新兴AKI生物标志物的样本。